Search

Memorial Sloan Kettering Cancer Center (MSK) announces its most recent awards and appointments for the institution’s physicians, scientists, nurses, and staff.

… Monday, August 17, 2020 Memorial Sloan Kettering Cancer Center (MSK) announces the following awards and appointments: Craig B. Thompson Named Founding Member of New York Jobs CEO Council Craig B. Thompson Craig B. Thompson, MD , President and Chief Executive Officer (CEO) of MSK, was named a founding

Lopez was recognized for his positive impact on New York City through his professional, communal, and philanthropic achievements.

… Tuesday, September 20, 2022 Jorge Lopez, Jr. , Executive Vice President (EVP) and General Counsel at Memorial Sloan Kettering Cancer Center (MSK), was recognized as a Notable Hispanic Leader and Executive in today’s Crain’s New York Business special editorial feature . This piece spotlights exceptional

Meet MSK Director of Social Work Penny Damaskos and learn how she and her team help people with cancer.

… Wednesday, April 25, 2018 At Memorial Sloan Kettering, social workers hope people cope with the logistical and emotional difficulties of cancer. Learn how Penny Damaskos, Director of Social Work at MSK, came into the field and what she’s learned about resilience along the way. She was recently awarded

MSK investigators find that the presence of certain gene mutations in patients’ blood may mean they are more likely to get a secondary leukemia.

… Thursday, August 10, 2017 Summary MSK investigators have found that the presence of certain gene mutations in patients’ blood may mean they are more likely to get a secondary leukemia. The discovery may lead to new methods for determining who is at greatest risk. One of the most devastating things that

Memorial Sloan Kettering Cancer Center (MSK) announces its most recent awards and appointments for the institution’s physicians, scientists, nurses, and staff.

… Thursday, May 7, 2020 Memorial Sloan Kettering Cancer Center (MSK) announces the following awards and appointments: Tsvi Gal Is Named MSK’s Head of Infrastructure Tsvi Gal Tsvi Gal Tsvi Gal has been appointed Head of Infrastructure of MSK. Mr. Gal assumed his role on April 28. Mr. Gal will lead the hospital

Men with advanced prostate cancer treated with radical prostatectomy and adjuvant radiotherapy have a lower risk of cancer-specific death and improved overall survival compared to men treated with radiotherapy plus androgen deprivation therapy.

… Thursday, November 8, 2018 Men with advanced prostate cancer treated with radical prostatectomy and adjuvant radiotherapy have a lower risk of cancer-specific death and improved overall survival compared to men treated with radiotherapy plus androgen deprivation therapy, according to our recent observational

Drs. Anna-Katerina Hadjantonakis and Robert Farese were elected to the 2026 class of the American Academy of Arts and Sciences.

… Thursday, April 23, 2026 Two Memorial Sloan Kettering Cancer Center (MSK) researchers were elected to the 2026 class of the American Academy of Arts and Sciences. Developmental biologist Anna-Katerina Hadjantonakis, PhD , and physician-scientist Robert Farese, Jr., MD , were among the 252 leaders in

Memorial Sloan Kettering researchers have found why certain drugs are not sufficiently effective in treating leukemias called myeloproliferative neoplasms.

… Thursday, September 6, 2012 Summary Memorial Sloan Kettering researchers have found why certain drugs are not sufficiently effective in treating leukemias called myeloproliferative neoplasms. Memorial Sloan Kettering researchers have discovered why a class of drugs called JAK2 inhibitors has not been

A pivotal international study published in the New England Journal of Medicine and led in part by José Baselga, MD, PhD, Physician-in-Chief at Memorial Sloan Kettering Cancer Center (MSK), offers proof of better treatment options for patients with HER2-positive early breast cancer. The new international research found that the drug pertuzumab (Perjeta®) significantly improved invasive-disease-free survival (IDFS) in patients with operable HER2-positive breast cancer when added to trastuzumab (Herceptin®) and chemotherapy. The findings of this study were presented at the American Society of Clinical Oncology annual meeting today in Chicago.

… Monday, June 5, 2017 A pivotal international study published in the New England Journal of Medicine and led in part by José Baselga, MD, PhD , Physician-in-Chief at Memorial Sloan Kettering Cancer Center (MSK), offers proof of better treatment options for patients with HER2-positive early breast cancer

MSK introduced its first new creative campaign in nearly two decades. The creative platform and campaign elements were developed and produced by MSK’s creative agency of record, Pereira & O’Dell New York.

… Tuesday, September 2, 2014 Memorial Sloan Kettering Cancer Center today introduced its first new creative campaign in nearly two decades: More Science. Less Fear. The creative platform and campaign elements were developed and produced by MSK’s creative agency of record, Pereira & O’Dell New York. MSK